# Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

> **NCT06512389** · PHASE2 · RECRUITING · sponsor: **Centre for Addiction and Mental Health** · enrollment: 36 (estimated)

## Conditions studied

- Alcohol Use Disorder

## Interventions

- **DRUG:** Oral solution

## Key facts

- **NCT ID:** NCT06512389
- **Lead sponsor:** Centre for Addiction and Mental Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-16
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06512389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06512389, "Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06512389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*